Drug Profile


Alternative Names: RP 5307; RP-5264; TGR-1202

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Incozen Therapeutics; Rhizen Pharmaceuticals
  • Developer Columbia University Medical Center; TG Therapeutics Inc; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Benzopyrans; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Casein kinase Iepsilon inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I/II Lymphoma
  • Phase I Hodgkin's disease; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Polycythaemia vera; Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 24 Jul 2017 Updated safety and efficacy data from a phase I trial in Follicular lymphoma and Diffuse large B cell lymphoma presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 20 Jul 2017 Chemical structure information added
  • 28 Jun 2017 TG Therapeutics initiates enrolment in a phase II trial for Chronic lymphocytic leukaemia (Combination therapy) in USA (IV) (NCT03207256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top